Viatris EBITDA 2010-2024 | VTRS

Viatris annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Viatris EBITDA for the quarter ending September 30, 2024 was $0.896B, a 20.82% decline year-over-year.
  • Viatris EBITDA for the twelve months ending September 30, 2024 was $2.527B, a 36.6% decline year-over-year.
  • Viatris 2023 annual EBITDA was $3.507B, a 24.47% decline from 2022.
  • Viatris 2022 annual EBITDA was $4.643B, a 3.8% increase from 2021.
  • Viatris 2021 annual EBITDA was $4.473B, a 123.03% increase from 2020.
Viatris Annual EBITDA
(Millions of US $)
2023 $3,507
2022 $4,643
2021 $4,473
2020 $2,005
2019 $2,735
2018 $3,016
2017 $3,243
2016 $2,222
2015 $2,493
2014 $1,919
2013 $1,652
2012 $1,656
2011 $1,516
2010 $1,144
2009 $925
Viatris Quarterly EBITDA
(Millions of US $)
2024-09-30 $896
2024-06-30 $546
2024-03-31 $895
2023-12-31 $190
2023-09-30 $1,131
2023-06-30 $1,056
2023-03-31 $1,130
2022-12-31 $668
2022-09-30 $1,260
2022-06-30 $1,271
2022-03-31 $1,443
2021-12-31 $672
2021-09-30 $1,375
2021-06-30 $1,269
2021-03-31 $1,156
2020-12-31 $72
2020-09-30 $784
2020-06-30 $550
2020-03-31 $600
2019-12-31 $820
2019-09-30 $793
2019-06-30 $597
2019-03-31 $525
2018-12-31 $842
2018-09-30 $839
2018-06-30 $681
2018-03-31 $654
2017-12-31 $945
2017-09-30 $760
2017-06-30 $895
2017-03-31 $643
2016-12-31 $790
2016-09-30 $315
2016-06-30 $714
2016-03-31 $403
2015-12-31 $765
2015-09-30 $859
2015-06-30 $535
2015-03-31 $334
2014-12-31 $561
2014-09-30 $629
2014-06-30 $355
2014-03-31 $374
2013-12-31 $415
2013-09-30 $467
2013-06-30 $427
2013-03-31 $343
2012-12-31 $391
2012-09-30 $506
2012-06-30 $384
2012-03-31 $374
2011-12-31 $372
2011-09-30 $407
2011-06-30 $406
2011-03-31 $331
2010-12-31 $207
2010-09-30 $339
2010-06-30 $297
2010-03-31 $301
2009-12-31 $164
2009-09-30 $165
2009-06-30 $273
2009-03-31 $322
Sector Industry Market Cap Revenue
Medical Medical Services $14.478B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $84.995B 10.55
Cencora (COR) United States $43.734B 16.44
DiDi Global (DIDIY) China $22.941B 0.00
Natera (NTRA) United States $20.871B 0.00
ICON (ICLR) Ireland $16.879B 15.03
Avantor (AVTR) United States $14.307B 21.45
Revvity (RVTY) United States $13.453B 23.37
BioMerieux (BMXMF) France $12.659B 0.00
CochLear (CHEOY) Australia $11.807B 0.00
Solventum (SOLV) United States $11.540B 0.00
Medpace Holdings (MEDP) United States $10.417B 29.35
Doximity (DOCS) United States $10.302B 60.64
Charles River Laboratories (CRL) United States $9.314B 18.00
HealthEquity (HQY) United States $8.212B 41.20
Sonic Healthcare (SKHHY) Australia $8.208B 0.00
Bausch + Lomb (BLCO) Canada $6.322B 29.43
Amplifon S.p.A (AMFPF) Italy $5.864B 29.89
Sotera Health (SHC) United States $3.759B 20.11
Organon (OGN) United States $3.719B 3.75
BrightSpring Health Services (BTSG) United States $2.967B 63.11
Surgery Partners (SGRY) United States $2.493B 28.42
Concentras Parent (CON) United States $2.491B 0.00
Ardent Health Partners (ARDT) United States $2.291B 0.00
GeneDx Holdings (WGS) United States $2.069B 0.00
Premier (PINC) United States $2.067B 10.76
PACS (PACS) United States $1.992B 0.00
Alignment Healthcare (ALHC) United States $1.969B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.730B 0.00
GoodRx Holdings (GDRX) United States $1.711B 44.90
Teladoc Health (TDOC) United States $1.544B 0.00
Pediatrix Medical (MD) United States $1.224B 11.98
Progyny (PGNY) United States $1.208B 24.47
Embecta (EMBC) United States $1.161B 8.12
CareDx (CDNA) United States $1.102B 0.00
Establishment Labs Holdings (ESTA) $1.090B 0.00
AMN Healthcare Services Inc (AMN) United States $0.874B 5.91
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Agilon Health (AGL) United States $0.775B 0.00
SBC Medicals (SBC) United States $0.649B 0.00
Auna S.A (AUNA) Luxembourg $0.492B 0.00
InnovAge Holding (INNV) United States $0.478B 0.00
DocGo (DCGO) United States $0.444B 16.73
Sonida Senior Living (SNDA) United States $0.441B 0.00
Enhabit (EHAB) United States $0.387B 33.48
Sera Prognostics (SERA) United States $0.275B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.268B 0.00
LifeMD (LFMD) United States $0.212B 0.00
Biodesix (BDSX) United States $0.198B 0.00
Beauty Health (SKIN) United States $0.176B 0.00
Nutex Health (NUTX) United States $0.160B 0.00
ModivCare (MODV) United States $0.156B 8.44
MultiPlan (MPLN) United States $0.108B 0.00
Ascend Wellness Holdings (AAWH) United States $0.099B 0.00
So-Young (SY) China $0.093B 15.69
IceCure Medical (ICCM) Israel $0.052B 0.00
Singular Genomics Systems (OMIC) United States $0.050B 0.00
OncoCyte (OCX) United States $0.037B 0.00
NeueHealth (NEUE) United States $0.033B 0.87
Pheton Holdings (PTHL) China $0.027B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.023B 0.00
Co-Diagnostics (CODX) United States $0.023B 0.00
Oncology Institute (TOI) United States $0.016B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
KindlyMD (KDLY) United States $0.007B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
Cano Health (CANOQ) United States $0.001B 0.00
Aclarion (ACON) United States $0.001B 0.00